A name assembled from four older firms.

The letters GSK are the end point of a long line of company names. According to Wikipedia, GSK plc takes its name as an abbreviation of its former name, GlaxoSmithKline, and that name in turn joined the names of two companies that were themselves the products of earlier mergers: Glaxo Wellcome and SmithKline Beecham.

The earliest of the strands began far from London. Wikipedia says Joseph Nathan and Co. was founded in 1873 as a general trading company in Wellington, New Zealand, by Joseph Edward Nathan, a Londoner. One of its products was first sold as Defiance and then under the name Glaxo, a word Wikipedia links to the Greek galaxias, “milky”. A sign for Glaxo Laboratories is still visible on the main street of Bunnythorpe, the New Zealand village where the business once worked. Glaxo Laboratories was incorporated as a separate subsidiary in London in 1935, and in 1947 the shareholders reorganised the group so that Glaxo became the parent company, with a listing on the London Stock Exchange. Glaxo acquired Allen & Hanburys in 1958.

The second strand was British from the start. Burroughs Wellcome & Company was founded in London in 1880 by two American pharmacists, Henry Wellcome and Silas Burroughs, Wikipedia says. In the 1970s its American arm commissioned the architect Paul Rudolph to design its new headquarters building in North Carolina. Glaxo and Wellcome merged in 1995 to form Glaxo Wellcome plc.

The third and fourth strands came together a few years earlier. Beecham traced its roots to Thomas Beecham, who began trading in England in 1848 and opened a factory in St Helens, Lancashire, in 1859. In the United States, SmithKline changed its name to SmithKline Beckman in 1982, and in 1989 SmithKline Beckman merged with the Beecham Group to form SmithKline Beecham, moving its headquarters from the United States to England, according to Wikipedia.

The two merged groups announced their intention to combine in January 2000, and the merger was completed on 27 December 2000, forming GlaxoSmithKline. The new company’s global headquarters became GSK House in Brentford, west London, officially opened in 2002. The three initials GSK were in use from the beginning as a shorthand; the long name stayed on the company’s legal title for more than two decades.

2022: a new name and the signal.

The shorthand became the official name in 2022. On 22 February 2022, Wikipedia says, GSK announced that its planned consumer healthcare spin-off would be called Haleon. On 16 May 2022 the company changed its name from GlaxoSmithKline to GSK, and on 18 July 2022 Haleon was formally spun off as a separate company. The rename and the separation of the consumer business came in the same season, and the visual identity followed within weeks.

The new identity was the work of the London brand consultancy Wolff Olins. Transform magazine reported its launch on 9 June 2022, describing it as an expression of GSK’s new purpose, which the company calls “Ahead Together”, and of its plan to focus on biopharma after the demerger. According to Transform, the agency drew inspiration from the imagery of bioscience, and the identity is built from numerous curves; the agency said these were meant to evoke adaptability.

The colour stayed. Transform wrote that GSK’s name was retained and that its orange logo was now housed in a redesigned shape known as the signal. The system was designed to flex, adapt and move across digital, social and physical settings, so the signal could work as a container on a screen, a building or a slide.

Type was part of the same project. The agency commissioned a custom typeface from the type foundry Face37, which uses ink traps to keep letters legible, Transform reported; the aim was to keep every asset clear and accessible on screen and in print. Emma Barratt, global executive creative director at Wolff Olins, told the magazine that the team had balanced a sense of adaptability with a need for warmth. The identity was introduced on the day of the announcement and was set to be rolled out across the whole business over the following months.

The result is an identity that relies on three elements: a set of initials, one saturated colour and one curved holding shape. None of them refers to a product, which lets the same mark sit on research sites, recruitment pages and annual reports without change.

Pharmaceutical names and their marks.

Pharmaceutical corporate identities are shaped as much by corporate history as by design. Many of the names in this sector were built through mergers, and the result is often a compound of two older names, a contraction of a longer one, or a set of initials that eventually replaces the full name altogether. A rename after a merger or a spin-off is usually the moment when a new logo, a new colour and a new typeface arrive together, presented as a single programme rather than a piecemeal refresh.

The marks themselves tend towards the abstract: interlocking shapes, simple geometric symbols or a plain wordmark, rather than pictures of anything specific. Palettes are often restrained, built around one signature colour with white space and a neutral supporting set, so that the same identity can sit on a corporate report, a laboratory building and a recruitment page without changing tone.

Promotion in this field is also regulated in many countries, with rules on what companies may say about medicines and to whom. That framework pushes corporate branding towards the company name, its values and its people, while product communication follows separate rules. The guides in this round look only at the corporate side: names, marks, colours and the dated changes behind them.

From Brentford to New Oxford Street.

The company’s address has changed along with its name. GSK House in Brentford served as the global headquarters from the early 2000s, and in July 2024, Wikipedia says, GSK moved its headquarters from Brentford to New Oxford Street in central London. Its United States headquarters are in Philadelphia, Pennsylvania, and Durham, North Carolina. The company has its primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index.

The 2022 changes also separated two families of brands. Before the spin-off, the consumer side of the business carried a range of household names; Transform noted in June 2022 that Haleon would take on a consumer portfolio including Sensodyne, Panadol and Advil. After July 2022 those names sat with Haleon, while the three letters GSK were left to stand for the biopharma company alone. In May 2024, according to Wikipedia, GSK sold its remaining shareholding in Haleon.

Seen together, the history explains why the identity is so spare. A name built from Glaxo, Wellcome, SmithKline and Beecham was long, and each of those words carried a history of its own. Reducing it to initials, then giving those initials one colour and one curved shape, gave the company a mark that does not have to describe any of the businesses that formed it.

For a design guide, GSK shows how a merged company can turn a long compound name into initials, keep its one recognisable colour through a redesign, and add a single holding shape and a custom typeface to carry the system. Compare AstraZeneca, another London-listed company formed by merger, and Bayer Aspirin for an older pharmaceutical trademark. For this guide we use signal orange, burnt orange, ink and peach with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep GSK’s identity on hand — save it to a board in the Made Good inspiration library.